David Faleck, MD
Gastroenterology · New York, NYNPI 1255607669
Payments from drug & device makers
Across 22 payments — averaging $11,899 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$249K
- Gilead$5K
- Ferring Pharmaceuticals Inc.$5K
- Mallinckrodt Hospital Products Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$317
- Aimmune Therapeutics, Inc.$34
What the payments were for
- Consulting fees$28,66099%
- Speaking & faculty fees$1400%
- Food & beverage$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 7 | $248,711 |
| Gilead | 4 | $5,213 |
| Ferring Pharmaceuticals Inc. | 1 | $4,650 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,860 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $317 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$261,786 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 16 | $330,896 |
| RinvoqUpadacitinib | 21 | $167,237 |
| CreonLipase/Protease/Amylase | 12 | $67,735 |
| Mesalamine | 118 | $66,586 |
| Mesalamine ErMesalamine | 21 | $8,566 |
| Budesonide EcBudesonide | 16 | $3,448 |
| Colesevelam Hcl | 11 | $1,923 |
| Budesonide DrBudesonide | 29 | $1,436 |
| Esomeprazole Magnesium | 19 | $890 |
| Omeprazole | 68 | $866 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $516 |
| Famotidine | 22 | $312 |
| Prednisone | 36 | $286 |
| Pantoprazole Sodium | 19 | $283 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.